Neuland Labs reported strong Q1FY27 financial results: total income rose 16.3% to INR650.1 Cr, EBITDA hit INR231.1 Cr (35.5% margin), and PAT reached INR147.4 Cr.

This performance, driven by commercial CMS projects, aligns with management expectations for a good start to the year.

The company's new peptide facility will commission next month with a visible order book.

Strategic growth includes expanding differentiated GDS products and a collaboration with Gland Pharma for sterile APIs.

Management aspires for ~20% growth in FY27-FY28, focusing on strategic customer partnerships and investing in complex modalities, expressing confidence in long-term value creation.